Story thread · 2 reports / 2 sources

AI brings savings to clinical trials: study

axios.com · 3h · first reportShare

Artificial intelligence isn't just speeding up early-stage drug development, it's starting to unlock millions of dollars' worth of new efficiencies in clinical trials on cancer treatments, research shared first with Axios shows. Why it matters: AI-powered tools could shave months off time-consuming processes like recruiting and enrolling patients, monitoring results and interpreting data. That could free up resources for more clinical studies and possibly lower the high failure rate for new drugs. What they found: A new Tufts Center for the Study of Drug Development analysis found AI agents can accelerate clinical development of cancer drugs by approximately 10 weeks and reduce direct operating costs by as much as $5.6 million in late-stage trials. The efficiencies increase with the number of tumors a drug can target: An experimental treatment with 50 active uses could see net benefits of as much as $565 million, Tufts found. Tufts applied a clinical monitoring agent from Medable, whic